Description
Herclon 440 Mg is a prescription drug for treatment of breast cancer. It is manufactured in USA and marketed by Roche. It is popularly known as ‘Herceptin‘ in Europe & America. The generic name for the medicine is Trastuzumab.
Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high risk feature.* Herceptin can be used in several different ways:
As part of a treatment course including the chemotherapy drugs Adriamycin® (doxorubicin), Cytoxan® (cyclophosphamide), and either Taxol® (paclitaxel) or Taxotere® (docetaxel). This treatment course is known as “AC→TH.”
With the chemotherapy drugs Taxotere and Paraplatin® (carboplatin). This treatment course is known as “TCH.”
Alone after treatment with multiple other therapies, including an anthracycline (Adriamycin)-based therapy (a type of chemotherapy).
